The immune ablative effects of the therapeutically active doses of free CDN were confirmed by loss of CD8+ T cells, macrophages, and DCs in the injected tumor with repetitive dosing (Fig. 4 and Supplementary Fig. 7). This evidence concerns the gene CD8A and neoplasm.